• 1
    Douek DC, Betts MR, Hill BJ et al. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol 2001; 167: 66636668.
  • 2
    Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006; 7: 235239.
  • 3
    Berrey MM, Schacker T, Collier AC et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001; 183: 14661475.
  • 4
    Kaufmann GR, Zaunders JJ, Cunningham P et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000; 14: 26432651.
  • 5
    Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001; 12: 133150.
  • 6
    Sinicco A, Biglino A, Sciandra M et al. Cytokine network and acute primary HIV-1 infection. AIDS 1993; 7: 11671172.
  • 7
    Biglino A, Sinicco A, Forno B et al. Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. Clin Immunol Immunopathol 1996; 78: 6169.
  • 8
    Amicosante M, Poccia F, Gioia C et al. Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection. J Infect Dis 2003; 188: 661665.
  • 9
    Goh LE, Perrin L, Hoen B et al. Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST Study. HIV Clin Trials 2001; 2: 438444.
  • 10
    Kinloch-de Loes S, Hoen B, Smith DE et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192: 607617.
  • 11
    Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 179183.
  • 12
    Salazar-Gonzalez JF, Martinez-Maza O, Nishanian P et al. Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection. J Infect Dis 1998; 178: 423430.
  • 13
    Fahey JL, Taylor JM, Manna B et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 1998; 12: 15811590.
  • 14
    Appay V, Boutboul F, Autran B. The HIV infection and immune activation: ‘to fight and burn’. Curr Infect Dis Rep 2005; 7: 473479.
  • 15
    Lindback S, Karlsson AC, Mittler J et al. Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS 2000; 14: 22832291.
  • 16
    Hel Z, McGhee JR, Mestecky J. HIV infection: first battle decides the war. Trends Immunol 2006; 27: 274281.
  • 17
    Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946954.
  • 18
    Birk M, Svedhem V, Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001; 15: 13591368.
  • 19
    Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8 T cells. Blood 2006; 107: 47814789.
  • 20
    Polo S, Veglia F, Malnati MS et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 1999; 13: 447454.
  • 21
    Aleman S, Pehrson P, Sonnerborg A. Kinetics of beta-chemokine levels during anti-HIV therapy. Antivir Ther 1999; 4: 109115.
  • 22
    Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS 1997; 11: 485491.
  • 23
    Aukrust P, Muller F, Froland SS. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis 1998; 177: 10911096.
  • 24
    Ye P, Kazanjian P, Kunkel SL, Kirschner DE. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J Lab Clin Med 2004; 143: 310319.
  • 25
    Brichacek B, Bukrinsky M. Highly active antiretroviral therapy and beta-chemokines. Clin Exp Immunol 2002; 130: 169171.
  • 26
    Torti C, Cologni G, Uccelli MC et al. Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART). Viral Immunol 2004; 17: 279286.
  • 27
    Falcone C, Minoretti P, D'Angelo A et al. Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease. Eur J Clin Invest 2006; 36: 211217.
  • 28
    Targowski T, Jahnz-Rozyk K, Plusa T, Glodzinska-Wyszogrodzka E. Influence of age and gender on serum eotaxin concentration in healthy and allergic people. J Investig Allergol Clin Immunol 2005; 15: 277282.
  • 29
    Tacke F, Trautwein C, Yagmur E et al. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol 2006; 8: 19.
  • 30
    Culley FJ, Pennycook AMJ, Tregoning JS, Hussell T, Openshaw PJM. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol 2006; 80: 45214527.
  • 31
    He J, Chen Y, Farzan M et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997; 385: 645649.
  • 32
    Choe H, Farzan M, Sun Y et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 11351148.
  • 33
    Modi WS, Goedert JJ, Strathdee S et al. MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS 2003; 17: 23572365.
  • 34
    Promadej-Lanier N, Srinivasan P, Curtis K et al. Systemic and mucosal immunological responses during repeated mucosal SHIV162P3 challenges prior to and following infection in pigtailed macaques. Virology 2008; 375: 492503.
  • 35
    Moanna A, Dunham R, Paiardini M, Silvestri G. CD4 T-cell depletion in HIV infection: killed by friendly fire? Curr HIV/AIDS Rep 2005; 2: 1623.
  • 36
    Bustin M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci STKE 2002; 151: PE39.
  • 37
    Wang H, Ward MF, Fan XG, Sama AE, Li W. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006; 19: 39.
  • 38
    Nowak P, Barqasho B, Sonnerborg A. Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection. AIDS 2007; 21: 869871.